Literature DB >> 22080978

l-carbocisteine inhibits respiratory syncytial virus infection in human tracheal epithelial cells.

Masanori Asada1, Motoki Yoshida, Yukimasa Hatachi, Takahiko Sasaki, Hiroyasu Yasuda, Xue Deng, Hidekazu Nishimura, Hiroshi Kubo, Ryoichi Nagatomi, Mutsuo Yamaya.   

Abstract

To examine the effects of l-carbocisteine on airway infection with respiratory syncytial (RS) virus, human tracheal epithelial cells were pretreated with l-carbocisteine and infected with RS virus. Viral titer, virus RNA, and pro-inflammatory cytokine secretion, including interleukin (IL)-1 and IL-6, increased with time after infection. l-carbocisteine reduced the viral titer in the supernatant fluids, the amount of RS virus RNA, RS virus infection susceptibility, and the concentration of pro-inflammatory cytokines induced by virus infection. l-carbocisteine reduced the expression of intercellular adhesion molecule (ICAM)-1, an RS virus receptor, on the cells. However, l-carbocisteine had no effects on the expression of heparan sulfate, a glycosaminoglycan that binds to the RS virus attachment protein, or on the amount of intracellular activated-RhoA, isoform A of the Ras-homologous family, that binds to the RS virus fusion protein. These findings suggest that l-carbocisteine may inhibit RS virus infection by reducing the expression of ICAM-1. It may also modulate airway inflammation during RS virus infection.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22080978     DOI: 10.1016/j.resp.2011.10.017

Source DB:  PubMed          Journal:  Respir Physiol Neurobiol        ISSN: 1569-9048            Impact factor:   1.931


  6 in total

1.  Carbocisteine attenuates TNF-α-induced inflammation in human alveolar epithelial cells in vitro through suppressing NF-κB and ERK1/2 MAPK signaling pathways.

Authors:  Wei Wang; Wei-Jie Guan; Rong-Quan Huang; Yan-Qing Xie; Jin-Ping Zheng; Shao-Xuan Zhu; Mao Chen; Nan-Shan Zhong
Journal:  Acta Pharmacol Sin       Date:  2016-03-21       Impact factor: 6.150

2.  Levofloxacin inhibits rhinovirus infection in primary cultures of human tracheal epithelial cells.

Authors:  Mutsuo Yamaya; Hidekazu Nishimura; Yukimasa Hatachi; Hiroyasu Yasuda; Xue Deng; Takahiko Sasaki; Katsumi Mizuta; Hiroshi Kubo; Ryoichi Nagatomi
Journal:  Antimicrob Agents Chemother       Date:  2012-05-14       Impact factor: 5.191

Review 3.  Pathophysiology of Clinical Symptoms in Acute Viral Respiratory Tract Infections.

Authors:  E Kuchar; K Miśkiewicz; Aneta Nitsch-Osuch; L Szenborn
Journal:  Adv Exp Med Biol       Date:  2015       Impact factor: 2.622

Review 4.  Clinical Efficacy of Carbocysteine in COPD: Beyond the Mucolytic Action.

Authors:  Elisabetta Pace; Isa Cerveri; Donato Lacedonia; Gregorino Paone; Alessandro Sanduzzi Zamparelli; Rossella Sorbo; Marcello Allegretti; Luigi Lanata; Francesco Scaglione
Journal:  Pharmaceutics       Date:  2022-06-14       Impact factor: 6.525

5.  Roflumilast inhibits respiratory syncytial virus infection in human differentiated bronchial epithelial cells.

Authors:  Manuel Mata; Isidoro Martinez; Jose A Melero; Herman Tenor; Julio Cortijo
Journal:  PLoS One       Date:  2013-07-23       Impact factor: 3.240

Review 6.  Redox Biology of Respiratory Viral Infections.

Authors:  Olga A Khomich; Sergey N Kochetkov; Birke Bartosch; Alexander V Ivanov
Journal:  Viruses       Date:  2018-07-26       Impact factor: 5.048

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.